UNSPSC 51292603: Aptazapine

This classification denotes an antidepressant agent with the molecular formula C16H19N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 240J927J1R chemically known as (+/-)-1,3,4,14b-tetrahydro-2-methyl-2h,10h-pyrazino(1,2-a)pyrrolo(2,1-c)(1,4)benzodiazepine but generally known as aptazapine, which bears US NIH Compound Identifier 51355. European Medicines Agency schedules Aptazapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05547MIG.

UNSPSC 51292603 Aptazapine is a Commodity code nominally associated with a specific pharmaceutical product, but the recent state and local opportunities tagged under it reflect broader pharmaceutical procurement activity — primarily generic multi-source drugs, over-the-counter products, and emergency medical supplies such as naloxone and drug deactivation systems. State and local governments buying under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that consolidate pharmaceutical sourcing across participating jurisdictions. The work includes competitive bidding for emergency medical countermeasures (naloxone kits), generic pharmaceutical supply agreements with volume commitments and quarterly delivery schedules, and exploratory market intelligence gathering around direct-to-manufacturer pharmacy benefit models. Vendors must typically meet FDA compliance, cGMP certification, Drug Supply Chain Security Act compliance, and established insurance thresholds; several opportunities require E-Verify confirmation and drug-free workplace certification.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, framed as exploratory market research before formal RFP release. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP in January 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026; evaluation weighted 75 percent on price competitiveness, with compliance, EDI capability, and administrative fee agreement comprising the remainder.